Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BUB1 | O43683 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4563138 | 1.00 | NFKB1 (0.32) | NFKB1NFKB2RELAGAAEPHX2 | |
| SCHEMBL13409202 | 1.00 | NFKB1 (0.32) | NFKB1NFKB2RELAGAAEPHX2 | |
| SCHEMBL3692487 | 0.83 | NFKB1 (0.32) | NFKB1NFKB2RELA | |
| SCHEMBL3302910 | 0.83 | NFKB1 (0.32) | NFKB1NFKB2RELA | |
| SCHEMBL13391516 | 0.69 | NFKB1 (0.31) | NFKB1NFKB2RELA | |
| SCHEMBL13409204 | 0.68 | USP2 (0.40) | MAPK1 | |
| SCHEMBL29243471 | 0.67 | NFKB1 (0.36) | NFKB1NFKB2RELAGAAMAPK10 | |
| SCHEMBL4790616 | 0.67 | NFKB1 (0.33) | NFKB1NFKB2RELAGAAEPHX2 | |
| SCHEMBL28763646 | 0.66 | LMNA (0.35) | NFKB1NFKB2RELAGAA | |
| SCHEMBL12295971 | 0.64 | EPHX2 (0.36) | EPHX2BUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592587-B2 | Transannular rearrangement of activated lactams | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2013-11-26 | — | — | US | disclosed |
| EP-2134681-B1 | TRANS-ANNULAR REARRANGEMENT OF ACTIVE LACTAMES | CENTRE NAT RECH SCIENT (FR) | 2012-05-16 | — | — | EP | disclosed |
| US-20100099874-A1 | TRANSANNULAR REARRANGEMENT OF ACTIVATED LACTAMS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2010-04-22 | — | — | US | disclosed |
| US-20100099874-A1 | TRANSANNULAR REARRANGEMENT OF ACTIVATED LACTAMS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099874-A1 | TRANSANNULAR REARRANGEMENT OF ACTIVATED LACTAMS | C9, RPS4Y1, C5 | NFKB1 691/4885NFKB2 907/4885RELA 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.